Switch theme
Sign up to access all valuation multiples
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
1991
407
LTM Revenue $299M
Last FY EBITDA $77.5M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MannKind has a last 12-month revenue (LTM) of $299M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, MannKind achieved revenue of $286M and an EBITDA of $77.5M.
MannKind expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MannKind valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $299M | XXX | $286M | XXX | XXX | XXX |
| Gross Profit | $254M | XXX | $209M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $77.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 27% | XXX | XXX | XXX |
| EBIT | $82.0M | XXX | $68.7M | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $41.9M | XXX | $27.6M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, MannKind's stock price is $4.
MannKind has current market cap of $1.3B, and EV of $1.1B.
See MannKind trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.3B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, MannKind has market cap of $1.3B and EV of $1.1B.
MannKind's trades at 3.9x EV/Revenue multiple, and 14.5x EV/EBITDA.
Equity research analysts estimate MannKind's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MannKind has a P/E ratio of 30.1x.
See valuation multiples for MannKind and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBIT | 13.7x | XXX | 16.4x | XXX | XXX | XXX |
| EV/Gross Profit | 4.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 30.1x | XXX | 45.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 34.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMannKind's last 12 month revenue growth is 12%
MannKind's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.
MannKind's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MannKind's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MannKind and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MannKind acquired XXX companies to date.
Last acquisition by MannKind was XXXXXXXX, XXXXX XXXXX XXXXXX . MannKind acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was MannKind founded? | MannKind was founded in 1991. |
| Where is MannKind headquartered? | MannKind is headquartered in United States of America. |
| How many employees does MannKind have? | As of today, MannKind has 407 employees. |
| Who is the CEO of MannKind? | MannKind's CEO is Mr. Michael E. Castagna, Pharm.D.. |
| Is MannKind publicy listed? | Yes, MannKind is a public company listed on NAS. |
| What is the stock symbol of MannKind? | MannKind trades under MNKD ticker. |
| When did MannKind go public? | MannKind went public in 2004. |
| Who are competitors of MannKind? | Similar companies to MannKind include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of MannKind? | MannKind's current market cap is $1.3B |
| What is the current revenue of MannKind? | MannKind's last 12 months revenue is $299M. |
| What is the current revenue growth of MannKind? | MannKind revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of MannKind? | Current revenue multiple of MannKind is 3.8x. |
| Is MannKind profitable? | Yes, MannKind is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
